Novavax (NVAX) Other Working Capital Changes (2010 - 2026)
Novavax (NVAX) posted quarterly Other Working Capital Changes of $10.3 million for Q4 2018, up 2189.29% year-over-year from $448000.0 in Q4 2017, and up 200.0% quarter-over-quarter from -$10.3 million in Q3 2018.
Novavax (NVAX) Other Working Capital Changes (2010 - 2026) Analysis & Trends
Novavax's Other Working Capital Changes history runs 6 years deep, the most recent figure standing at $10.3 million for Q4 2018.
- In Q4 2018, Other Working Capital Changes rose 2189.29% year-over-year to $10.3 million; the TTM figure through Sep 2018 stood at -$9.8 million (down 384.45% YoY), while the FY2017 annual figure was $1.9 million, down 1.53% from the prior year.
- Other Working Capital Changes for Q4 2018 stood at $10.3 million, up from -$10.3 million in the prior quarter.
- The five-year high for Other Working Capital Changes was $698.9 million in Q2 2025, with the low at -$604.0 million in Q1 2025.
- The 5-year median for Other Working Capital Changes is -$51.0 million (2026), against an average of -$34.2 million.
- The sharpest annual moves came in 2017 and 2018: Other Working Capital Changes sank 87.93% in 2017, then surged 2189.29% in 2018.
- Novavax's Other Working Capital Changes stood at $2.8 million in 2015, then retreated by 29.69% to $2.0 million in 2016, then tumbled by 77.18% to $448000.0 in 2017, then soared by 2189.29% to $10.3 million in 2018.
- Business Quant data shows NVAX's Other Working Capital Changes at $10.3 million in Q4 2018, -$10.3 million in Q3 2018, and $448000.0 in Q4 2017.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Novavax | 1.33 Bn | 607.37 Mn | 42.45 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -8.87 Mn |
| Jun 30, 2026 | -8.87 Mn |
| Jun 30, 2026 | -8.87 Mn |
| Mar 31, 2026 | -50.95 Mn |
| Mar 31, 2026 | -50.95 Mn |
| Mar 31, 2026 | -50.95 Mn |
| Dec 31, 2025 | -509.96 Mn |
| Dec 31, 2025 | -509.96 Mn |
| Dec 31, 2025 | -509.96 Mn |
| Sep 30, 2025 | -207.93 Mn |
| Sep 30, 2025 | -207.93 Mn |
| Sep 30, 2025 | -207.93 Mn |
| Jun 30, 2025 | 698.94 Mn |
| Jun 30, 2025 | 698.94 Mn |
| Jun 30, 2025 | 698.94 Mn |
| Mar 31, 2025 | -604.00 Mn |
| Mar 31, 2025 | -604.00 Mn |
| Mar 31, 2025 | -604.00 Mn |
| Dec 31, 2024 | 420.28 Mn |
| Dec 31, 2024 | 420.28 Mn |